glycerin
Approved
May 6, 1982
Glycerin (glycerol) is 3-carbon alcohol naturally occurring in the human body. It is the structural backbone triacylglycerol molecules, and can also be converted to a glycolytic substrate for subsequent metabolism. Glycerin is a colorless, odorless, viscous, sweet-tasting liquid. The FDA classifies glycerol as "generally recognized as safe". Glycerin is used in the pharmaceutical industry as a sweetener in syrups, lozenges, and as an excipient in eyewash solutions. As an individual prescription product, glycerin has uses as a hyperosmotic, osmotic diuretic, and ophthalmic agent. It may be used as an eye drop in the treatment of glaucoma to reduce intraocular pressure, as a solution or suppository for short-term treatment of constipation, to evacuate the bowel prior to a colonoscopy, and in some ocular surgeries. It may be given intravenously to reduce pressure inside the brain and used externally on the skin as a moisturizer. Glycerin has many other uses in the agricultural, food and pharmaceutical industry. — NCATS
Clinical trial activity
69 trials · 89 clinical orgs · 1 marketing orgs
Earliest trial started Oct 1, 1999 (NCT00005889)
Timeline
Indications
Studied for
- Autism Spectrum Disorder · Phase 4
- Breast Neoplasms · Phase 2
- Burns · Phase 4
- Cataract · Phase 4
- Constipation · Phase 3
- Coronavirus Infections · Phase 2
- COVID-19 · Phase 2
- Dentin Sensitivity · Phase 4
- Dermatitis, Atopic · Phase 3
- Dermatitis, Contact · Phase 4
- Dermatitis, Occupational · Phase 4
- Dermatology · Phase 4
- Disease Progression · Phase 4
- Dry Eye Syndromes · Phase 4
- Encopresis · Phase 4
- Exanthema · Phase 2
- Eye Diseases · Phase 4
- Fecal Incontinence · Phase 4
- Food Hypersensitivity · Phase 2
- Gastroschisis · Phase 4
- Headache Disorders · Phase 1/Phase 2
- Hearing Loss · Phase 4
- Hysterectomy · Phase 4
- Keratoconjunctivitis Sicca · Phase 4
- Lacrimal Apparatus Diseases · Phase 2
- Meningitis, Bacterial · Phase 3
- Nails, Malformed · Phase 3
- Neurogenic Bowel · Phase 4
- Obesity, Abdominal · Phase 4
- Otitis · Phase 4
- Otitis Media · Phase 3
- Pancreatitis · Phase 4
- Parenteral Nutrition · Phase 4
- Peanut Hypersensitivity · Phase 2
- Pharyngeal Diseases · Phase 2
- Postmenopause · Phase 2
- Postoperative Pain · Phase 4
- Retinal Diseases · Phase 2/Phase 3
- SARS-CoV-2 · Phase 2
- Severity of Illness Index · Phase 4
- Skin Aging · Phase 4
- Skin Diseases · Phase 1/Phase 2
- Staining and Labeling · Phase 4
- Survivors · Phase 2
- Tears · Phase 4
- Trigeminal Neuralgia · Phase 1/Phase 2
- Vaginal Diseases · Phase 2
- Vertigo · Phase 4
- Virus Diseases · Phase 2
- Vitreoretinopathy, Proliferative · Phase 2/Phase 3
Mechanism of action
- UnclearUnclear
Unclear unclear
Combination products
procalamine
with calcium, potassium chloride, phosphoric acid, sodium acetate, amino acids, sodium chloride, magnesium
Approval history
- approvedMay 6, 1982
- approvedMay 6, 1982
Chemistry & pharmacology
SMILES
OCC(O)CO- Mol. weight
- 92.0938 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaLubriderm ↗
- NCATSPDC6A3C0OX ↗
- ChEMBLCHEMBL692 ↗
- WikipediaGlycerol ↗
- WikipediaEndura ↗
Also known as
- 1,2,3-propanetriol
- 1,2,3-propanetriol
- 1,2,3-triglycerol
- 1,2,3-trihydroxypropane
- 1,2,3-trihydroxypropane
- 2-chloro-n-(4-chlorobiphenyl-2-yl)nicotinamide
- boscalid
- boscalid
- boscalid
- e422
- e422
- endura
- endura
- endura
- glycerin
- glycerin
- glycerin
- glycerin
- glycerin
- glycerin
- glycerin
- glycerin,anhydrous
- glycerin,anhydrous
- glycerin, anhydrous
- glycerin, anhydrous
- glycerine
- glycerine
- glycerine
- glycérine
- glycérine
- glycerinum
- glycerinum
- glycerol
- glycerol
- glycerol
- glycerol
- glycerol
- glycerol
- glycerol
- glycerol
- glycérol
- glycérol
- glycogelatin
- glycyl alcohol
- glyzerin
- glyzerin
- keybells
- lubriderm
- monoctanoin component d
- monoctanoin component d
- monoctanoin component d
- nirolex
- ölsüß
- ölsüß
- ophthalgan
- ophthalgan
- optim
- optim
- osmoglyn
- osmoglyn
- propane-1,2,3-triol
- propanetriol
- propanetriol
- senokot direct relief
- taponoto
- tixylix baby
- tixylix toddler
- trihydroxypropane
- trihydroxypropane
- waterhouse
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07226739 | Phase 4 | Jan 31, 2026 | Emory University, National Institutes of Health (NIH) |
| NCT07284381 | Phase 3 | Dec 15, 2025 | AbbVie |
| NCT06048614 | N/A | Sep 30, 2023 | Duke University, KK Women's and Children's Hospital, National University of Singapore, Singapore General Hospital, SingHealth Investigational Medicine Unit |
| NCT05660447 | Phase 2/Phase 3 (Phase 3) | Dec 19, 2022 | Thomas Jefferson University |
| NCT05660681 | N/A | Dec 12, 2022 | Andover Research Eye Institute, Calm Water Therapeutics LLC |
| NCT05217160 | Phase 4 | May 11, 2021 | The Metis Foundation |
| NCT04493333 | Phase 2 | Dec 31, 2020 | AMAG Pharmaceuticals, Inc., University of Arkansas |
| NCT05057351 | N/A | Sep 1, 2020 | Complife Italia Srl, Greenpharma S.A.S. |
| NCT04409873 | Phase 2 | Jul 1, 2020 | University of California, San Francisco |
| NCT03978338 | N/A | Jul 31, 2019 | Chinese Academy of Medical Sciences, Zhitong Biopharma CO.,LTD |
| NCT04855279 | N/A | Jan 7, 2019 | Istanbul Medipol University |
| NCT02942082 | N/A | Nov 1, 2017 | Cairo University |
| NCT03197922 | Phase 3 | Oct 25, 2017 | Department of Defense, Emory University |
| NCT03355326 | Phase 4 | Oct 1, 2017 | Indiana University |
| NCT04253704 | Phase 1/Phase 2 (Phase 2) | Feb 13, 2017 | Cantor Research Laboratory, Sytheon Ltd. |
| NCT02936830 | Phase 4 | Oct 1, 2016 | Riyadh Colleges of Dentistry and Pharmacy |
| NCT02797067 | Phase 4 | Sep 1, 2016 | Changhai Hospital |
| NCT02811289 | N/A | Aug 5, 2016 | Centre de Recherche Clinique du CHUS, University of Sherbrooke |
| NCT03657407 | Phase 4 | Jun 1, 2016 | Mercy Medical Center, University of Maryland |
| NCT02624661 | Phase 1/Phase 2 (Phase 2) | May 1, 2016 | Norwegian University of Science and Technology |
Organizations
Research & Development (89)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergan | For profit | 13 | 9 | 4 | 2004 |
| Emory University | Academic/Hospital | 3 | 3 | 3 | 2015 |
| Thomas Jefferson University | Academic/Hospital | 3 | 3 | 3 | 2004 |
| Baylor University | Academic/Hospital | 2 | 1 | 1 | 1999 |
| Ferring | For profit | 2 | 2 | 2 | 2010 |
| Innovative Medical Research of South Florida, Inc | For profit | 2 | 2 | 1 | 2007 |
| The University of Texas, Dallas | Academic/Hospital | 2 | 1 | 2 | 2014 |
| University of Rochester | Academic/Hospital | 2 | 1 | 1 | 2008 |
| AbbVie | For profit | 1 | 1 | 1 | 2025 |
| AMAG Pharmaceuticals, Inc. | For profit | 1 | 0 | 1 | 2020 |
| Andover Research Eye Institute | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Arbor Pharmaceuticals | For profit | 1 | 1 | 1 | 2013 |
| Arrayan Hospital | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Bayer | For profit | 1 | 0 | 1 | 2008 |
| Bp Consulting, Inc | For profit | 1 | 1 | 1 | 2008 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Calm Water Therapeutics LLC | For profit | 1 | 1 | 1 | 2022 |
| Cantor Research Laboratory | For profit | 1 | 0 | 1 | 2017 |
| Centre de Recherche Clinique du CHUS | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Changhai Hospital | Academic/Hospital | 1 | 1 | 1 | 2016 |